VALENCIA, Calif.--(BUSINESS WIRE)--MannKind Corporation (NASDAQ:MNKD) today announced the first patient has been dosed in a phase 2 clinical trial of the novel, investigational cancer vaccine MKC1106-MT. As a part of MannKind’s cancer immunotherapy program, this phase 2 study will evaluate the safety, tolerability, immune response and clinical response of MKC1106-MT in patients with advanced melanoma. In a previous phase 1 study, repeat intranodal administration of the treatment regimen was well-tolerated and generated immune responses meeting the primary endpoints of the study. The phase 1 study also generated encouraging objective responses in a subset of patients with disease localized to the lymphatic system. Final results of the phase 1 study were presented as a poster at the annual meeting of the American Society of Clinical Oncology (ASCO) in June 2010.
